{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"310.09","value":"151.4"},{"groupId":"OG001","spread":"188.46","value":"86.5"}]}],"title":"24 hours post dose (n= 45, 27)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"116.89","value":"42.5"},{"groupId":"OG001","spread":"73.37","value":"26.9"}]}],"title":"72 hours post dose (n=45, 36)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"8.83","value":"5.4"},{"groupId":"OG001","spread":"6.56","value":"4.9"}]}],"title":"7 days post dose (n=67, 39)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"193.64","value":"31.0"},{"groupId":"OG001","spread":"19.75","value":"8.5"}]}],"title":"4 weeks post dose (n=52, 35)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"4.26","value":"4.2"},{"groupId":"OG001","spread":"8.36","value":"5.4"}]}],"title":"8 weeks post dose (n=45, 37)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.62","value":"10.7"},{"groupId":"OG001","spread":"22.98","value":"7.8"}]}],"title":"12 weeks post dose (n=42, 33)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"},{"groupId":"OG001","value":"39"}],"units":"Participants"}],"description":"Serum Amyloid A Protein (SAA) levels were determined in blood serum in order to identify the presence of inflammation, to determine its severity, and to monitor the response to treatment. Analytes were measured by a central laboratory. The treatment effect reported for canakinumab arm was for last post-baseline flare after re-treated with canakinumab and for patient which switched to Canakinumab arm was for first post-baseline flare after receiving the first dose of canakinumab.","dispersionType":"Standard Deviation","groups":[{"description":"Patients received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 weeks extension study for any new gout flare on demand with the same treatment as assigned in the core study.","id":"OG000","title":"Randomized to Canakinumab and Re-treated With Canakinumab"},{"description":"Patients received 1 intramuscular (im) injection of triamcinolone acetonide 40 mg and 1 subcutaneous (sc) injection of placebo to canakinumab on Day 1. Patients could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed after the previous dose. Patients completing the 12 weeks core study were allowed to continue to be treated in another 12 week extension study for any new gout flare on demand with the same treatment as assigned in the core study.\n\nPatients under this arm who agreed to continue to 2nd extension period of 12 months, were switched to canakinumab 150 mg sc for any new gout flare during this period","id":"OG001","title":"Randomized to Triamcinolone and Switched to Canakinumab"}],"paramType":"MEAN","populationDescription":"Modified Analysis Set (MAS) consists of all FAS patients who were either re-treated or switched to canakinumab during 72 weeks. At each timepoint only patients with a value at both baseline flare and the new flare are included","reportingStatus":"POSTED","timeFrame":"24 hours, 72 hours, 7 days, 4 weeks, 8 weeks and 12 weeks post-dose for the last post-baseline flare for patients re-treated with canakinumab or first post-baseline flare treated with canakinumab for patients switched treatment (during 72 weeks overall)","title":"Serum Amyloid A Protein (SAA) Levels for Patients Re-treated With or Switched to Canakinumab","type":"SECONDARY","unitOfMeasure":"mg/L"}